ATE374212T1 - Neue kalium-kanäle und dafür kodierende gene - Google Patents

Neue kalium-kanäle und dafür kodierende gene

Info

Publication number
ATE374212T1
ATE374212T1 AT00931037T AT00931037T ATE374212T1 AT E374212 T1 ATE374212 T1 AT E374212T1 AT 00931037 T AT00931037 T AT 00931037T AT 00931037 T AT00931037 T AT 00931037T AT E374212 T1 ATE374212 T1 AT E374212T1
Authority
AT
Austria
Prior art keywords
potassium channels
genes coding
channels
kcnq5
new potassium
Prior art date
Application number
AT00931037T
Other languages
English (en)
Inventor
Thomas Jentsch
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Application granted granted Critical
Publication of ATE374212T1 publication Critical patent/ATE374212T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00931037T 1999-06-11 2000-05-29 Neue kalium-kanäle und dafür kodierende gene ATE374212T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA199900828 1999-06-11

Publications (1)

Publication Number Publication Date
ATE374212T1 true ATE374212T1 (de) 2007-10-15

Family

ID=8098013

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00931037T ATE374212T1 (de) 1999-06-11 2000-05-29 Neue kalium-kanäle und dafür kodierende gene

Country Status (6)

Country Link
EP (1) EP1194447B1 (de)
JP (1) JP4833467B2 (de)
AT (1) ATE374212T1 (de)
AU (1) AU4911000A (de)
DE (1) DE60036548T2 (de)
WO (1) WO2000077035A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058952A2 (en) * 2000-02-10 2001-08-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, The National Institutes Of Health Constitutively open voltage-gated k+ channels and methods for discovering modulators thereof
DE10013732A1 (de) * 2000-03-21 2001-09-27 Aventis Pharma Gmbh Das Kaliumkanalprotein KCNQ5, ein neuer Angriffspunkt bei Erkrankungen des zentralen Nervensystems und des Herz-Kreislauf-Systems
US7049137B2 (en) * 2000-03-21 2006-05-23 Icagen, Inc. KCNQ5, a novel potassium channel
US6617131B2 (en) 2000-03-21 2003-09-09 Aventis Pharma Deutschland Gmbh Nucleic acid molecule encoding the potassium channel protein, KCNQ5
EP1272634A1 (de) * 2000-04-03 2003-01-08 Lexicon Genetics Incorporated Humaner ionenkanal und polynukleotide dafür
WO2001092526A1 (en) * 2000-05-26 2001-12-06 Bristol-Myers Squibb Company Human kcnq5 potassium channel, methods and compositions thereof
NZ513755A (en) 2001-08-24 2001-09-28 Ann Rachel Holmes Protein expression system in yeast comprising a vector encoding a heterologous membrane protein and its application in screening for drugs
WO2005075674A1 (en) * 2004-02-04 2005-08-18 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of kcne4 gene and protein for alzheimer disease
US7517960B2 (en) 2006-01-19 2009-04-14 Wyeth Rat KCNQ5 voltage-gated potassium channel

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1007638T3 (da) * 1997-08-12 2007-05-21 Bristol Myers Squibb Co KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf
CA2307316C (en) * 1997-10-24 2010-12-21 University Of Utah Research Foundation Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies

Also Published As

Publication number Publication date
WO2000077035A3 (en) 2001-05-10
WO2000077035A2 (en) 2000-12-21
DE60036548T2 (de) 2008-06-26
EP1194447A2 (de) 2002-04-10
JP2003527082A (ja) 2003-09-16
AU4911000A (en) 2001-01-02
JP4833467B2 (ja) 2011-12-07
DE60036548D1 (de) 2007-11-08
EP1194447B1 (de) 2007-09-26

Similar Documents

Publication Publication Date Title
Plumb et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954
MA27986A1 (fr) Inhibiteurs de kinesine mitotique
MXPA03000634A (es) Metodos para el reemplazo, el desplazamiento y acumulacion de adn en genomas eucarioticos.
ZA200405388B (en) Binding proteins as biosensors
DE60031241D1 (de) Kaliumkanäle und für diese kaliumkanäle kodierende gene
DE60228212D1 (de) Neue expressionsvektoren
DE60031997D1 (de) Umkehrtransfektionsverfahren
TW200611910A (en) Interferon-alpha polypeptides and conjugates
DE60036548D1 (de) Neue kalium-kanäle und dafür kodierende gene
DE60310251D1 (de) Platin-freier elektrokatalysator
ATE333520T1 (de) Neuartige polynukleotide und polypeptide des ifnalpha-21 gens
ATE310085T1 (de) Cyclin-e2 proteine und dafür kodierende gene
DE60031967D1 (de) Neuartige menschliche kalium-potentialabhängige kanäle
Wang et al. Retrovirus-mediated transfer of the human O6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents.
DE69321720D1 (de) Für den interleukin-9-rezeptor kodierende nukleinsäuresequenzen bzw. dafür komplementäre nuleinsäuresequenzen
ATE383421T1 (de) Reversible, parallele und zur vielfältigen aufgabenbewältigung verwendbare (multitask) klonierungsmethode und entprechende reagentien
SG95698A1 (en) Dna for encoding d-hydantoin hydrolases, dna for encoding n-carbamyl-d-amino acid hydrolases, recombinant dna containing the genes, cells transformed with the recombinant dna, methods for producing pr
BR0316224A (pt) Sequência de dna da região genÈmica tcd de photorhabdus luminescens
GB2358865A (en) Targeted gene modification by parvoviral vectors
ATE312933T1 (de) Promotoren zur kontrolle der zelldifferenzierung
DK1634955T3 (da) Konditionale genvektorer, der er reguleret i cis
ATE417066T1 (de) Modifizierte cdna für hohe expressionsniveaus von faktor viii und dessen derivaten
DE69631899D1 (de) Xylanasen, für diese kodierende gene und anwendungen derselben
NZ512332A (en) Potassium channel interactors and uses therefor
ATE355385T1 (de) Herstellung von rekombinanten adenoviren und von adenovirus-genbanken

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties